JP5483816B2 - アルツハイマー病に関する方法及び組成物 - Google Patents

アルツハイマー病に関する方法及び組成物 Download PDF

Info

Publication number
JP5483816B2
JP5483816B2 JP2007534083A JP2007534083A JP5483816B2 JP 5483816 B2 JP5483816 B2 JP 5483816B2 JP 2007534083 A JP2007534083 A JP 2007534083A JP 2007534083 A JP2007534083 A JP 2007534083A JP 5483816 B2 JP5483816 B2 JP 5483816B2
Authority
JP
Japan
Prior art keywords
protein
alzheimer
disease
differentially expressed
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007534083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514946A (ja
Inventor
ジュール・ウェストブルック
ヘレン・バイヤーズ
マルコム・ワード
サイモン・ラブストーン
アブドゥル・ハイ
スティーブン・リンハム
リシャール・ジュベール
ペトラ・プレフォット
カールシュテン・クーン
クリスティアン・バウマン
ユルゲン・シェーファー
トルシュテン・プリンツ
シュテファン・キーンレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of JP2008514946A publication Critical patent/JP2008514946A/ja
Application granted granted Critical
Publication of JP5483816B2 publication Critical patent/JP5483816B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2007534083A 2004-09-29 2005-09-29 アルツハイマー病に関する方法及び組成物 Expired - Lifetime JP5483816B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0421639.6A GB0421639D0 (en) 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease
GB0421639.6 2004-09-29
PCT/GB2005/003756 WO2006035237A2 (en) 2004-09-29 2005-09-29 Methods and compositions relating to alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011128088A Division JP5893269B2 (ja) 2004-09-29 2011-06-08 アルツハイマー病に関する方法及び組成物

Publications (2)

Publication Number Publication Date
JP2008514946A JP2008514946A (ja) 2008-05-08
JP5483816B2 true JP5483816B2 (ja) 2014-05-07

Family

ID=33397455

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007534083A Expired - Lifetime JP5483816B2 (ja) 2004-09-29 2005-09-29 アルツハイマー病に関する方法及び組成物
JP2011128088A Expired - Lifetime JP5893269B2 (ja) 2004-09-29 2011-06-08 アルツハイマー病に関する方法及び組成物
JP2014159434A Pending JP2014209132A (ja) 2004-09-29 2014-08-05 アルツハイマー病に関する方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011128088A Expired - Lifetime JP5893269B2 (ja) 2004-09-29 2011-06-08 アルツハイマー病に関する方法及び組成物
JP2014159434A Pending JP2014209132A (ja) 2004-09-29 2014-08-05 アルツハイマー病に関する方法及び組成物

Country Status (10)

Country Link
US (2) US7897361B2 (https=)
EP (3) EP2562545A1 (https=)
JP (3) JP5483816B2 (https=)
AT (1) ATE495445T1 (https=)
AU (1) AU2005288689B2 (https=)
CA (1) CA2580532C (https=)
DE (1) DE602005025897D1 (https=)
DK (1) DK2354795T3 (https=)
GB (1) GB0421639D0 (https=)
WO (1) WO2006035237A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
GB0426859D0 (en) * 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2344881A4 (en) * 2008-09-26 2012-03-07 Univ Melbourne BIOMARKER FOR MORBUS ALZHEIMER
IT1392551B1 (it) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
US20120071337A1 (en) 2009-01-26 2012-03-22 Electrophoretics Limited Methods
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
AU2010202926B2 (en) * 2009-09-11 2016-07-14 Electrophoretics Limited Markers and methods relating to the assessment of Alzheimer's disease
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP5906519B2 (ja) * 2011-09-13 2016-04-20 国立大学法人 熊本大学 二次元電気泳動による蛋白質の分離方法
JP2014533834A (ja) * 2011-11-18 2014-12-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスサイレチンおよびそのアイソフォームの定量化
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
WO2013148166A1 (en) 2012-03-29 2013-10-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behlaf Of Arizona State University Nanoscale process to generate reagents selective for individual protein variants
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
WO2013153461A2 (en) 2012-04-13 2013-10-17 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
WO2014040042A2 (en) 2012-09-10 2014-03-13 The Johns Hopkins University Diagnostic assay for alzheimer's disease
WO2014055683A1 (en) * 2012-10-03 2014-04-10 The Research Foundation For The State University Of New York Spectroscopic method for alzheimer's disease diagnosis
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
CA2902068C (en) * 2013-02-28 2023-10-03 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
GB201310203D0 (en) * 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
GB201310150D0 (en) * 2013-06-07 2013-07-24 Electrophoretics Ltd Methods and compositions relating to alzheimer's disease
EP3039431A4 (en) * 2013-08-27 2017-05-03 CRC for Mental Health Ltd. Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
GB201322094D0 (en) 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
CA2936056A1 (en) * 2014-01-06 2015-07-09 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
US10639322B2 (en) * 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US9904961B2 (en) 2015-05-07 2018-02-27 Kuwait University System and method for determining the feedback capacity of information distributed in a complex network
JP6193942B2 (ja) * 2015-09-09 2017-09-06 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN105403649B (zh) * 2015-12-01 2018-03-20 深圳大学 一种检测ad的尿液多肽组ad生物标记物
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JP6947450B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
WO2019013341A1 (ja) * 2017-07-14 2019-01-17 株式会社島津製作所 疾患検出方法
JP6408087B2 (ja) * 2017-07-25 2018-10-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
CN113024651A (zh) * 2019-12-25 2021-06-25 中国医学科学院药物研究所 阿尔茨海默病生物标志物及其应用
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
CN115808492A (zh) * 2021-09-14 2023-03-17 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物天冬酰胺及其应用
EP4605754A1 (en) * 2022-10-18 2025-08-27 Immungenetics AG Identifying a subject suffering from alzheimer's dementia or being at risk of developing alzheimer's dementia
CN117831756B (zh) * 2024-03-05 2024-06-28 精智未来(广州)智能科技有限公司 一种认知障碍的辅助分析方法、装置、设备及存储介质

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
US20030211622A1 (en) 1998-06-29 2003-11-13 Roberts L. Jackson Methods and compositions to assess oxidative brain injury
US20030131364A1 (en) * 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
JP2001249128A (ja) * 2000-03-06 2001-09-14 Ikagaku:Kk 動脈硬化症またはアルツハイマー病の診断用キット
US20020174447A1 (en) * 2001-01-23 2002-11-21 Greenspan Ralph J. Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease
US6528309B2 (en) * 2001-03-19 2003-03-04 The Regents Of The University Of California Vacuum-mediated desiccation protection of cells
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
US20070128596A1 (en) * 2002-07-03 2007-06-07 Roninson Igor B Reagents and methods for identifying and modulating expression of tumor senescence genes
WO2004030522A2 (en) * 2002-10-02 2004-04-15 Dmi Biosciences, Inc. Diagnosis and monitoring of diseases
KR100595494B1 (ko) * 2003-02-24 2006-07-03 (주) 디지탈바이오텍 혈액 내 베타-아밀로이드 항체 농도를 이용한 알츠하이머병 진단키트
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease

Also Published As

Publication number Publication date
EP2354795B1 (en) 2014-12-17
US20080070995A1 (en) 2008-03-20
AU2005288689A1 (en) 2006-04-06
WO2006035237A2 (en) 2006-04-06
CA2580532A1 (en) 2006-04-06
JP2014209132A (ja) 2014-11-06
EP2354795A1 (en) 2011-08-10
DE602005025897D1 (de) 2011-02-24
AU2005288689B2 (en) 2011-10-27
ATE495445T1 (de) 2011-01-15
GB0421639D0 (en) 2004-10-27
EP2562545A1 (en) 2013-02-27
CA2580532C (en) 2019-06-25
JP2011209291A (ja) 2011-10-20
EP1794594B1 (en) 2011-01-12
EP1794594A2 (en) 2007-06-13
JP2008514946A (ja) 2008-05-08
DK2354795T3 (en) 2015-02-16
US7897361B2 (en) 2011-03-01
US20110165146A1 (en) 2011-07-07
JP5893269B2 (ja) 2016-03-23
WO2006035237A3 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
JP5483816B2 (ja) アルツハイマー病に関する方法及び組成物
JP6803230B2 (ja) アルツハイマー病に関するバイオマーカー及び方法
US20260091025A1 (en) Biomolecules involved in alzheimer's disease
Hu et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease
JP2015111124A (ja) アルツハイマー病に関する方法及び組成物
US20220155295A1 (en) Predictive Markers Useful in the Treatment of Wet Age-Related Macular Degeneration
KR102569948B1 (ko) 암 검출 방법
AU2011253636B2 (en) Methods and compositions relating to alzheimer's disease

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140218

R150 Certificate of patent or registration of utility model

Ref document number: 5483816

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term